MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on April 11, 2007; DOI: 10.1124/mol.107.034447


0026-895X/07/7201-62-72$20.00
Mol Pharmacol 72:62-72, 2007

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.107.034447v1
72/1/62    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kim, E. J.
Right arrow Articles by Ha, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, E. J.
Right arrow Articles by Ha, J.

Antidiabetes and Antiobesity Effect of Cryptotanshinone via Activation of AMP-Activated Protein Kinase

Eun Ju Kim, Seung-Nam Jung, Kun Ho Son, Sung Ran Kim, Tae Youl Ha, Myoung Gyu Park, In Gun Jo, Jong Guk Park, Wonchae Choe, Sung-Soo Kim, and Joohun Ha

Department of Biochemistry and Molecular Biology, Medical Research Center for Bioreaction to Reactive Oxygen Species, Kyung Hee University School of Medicine, Seoul, Korea (E.J.K., S.-N.J., W.C., S.-S.K., J.H.); Department of Food Science and Nutrition, Andong National University, Andong, Korea (K.H.S.); Food Function Research Division, Korea Food Research Institute, Sungnam, Korea (S.R.K., T.Y.H.); and New Drug Research Division, MD Bioalpha Co., Ltd., Sungnam, Korea (M.G.P., I.G.J., J.G.P.)

Metabolic disorders, including type 2 diabetes and obesity, represent major health risks in industrialized countries. AMP-activated protein kinase (AMPK) has become the focus of a great deal of attention as a novel therapeutic target for the treatment of metabolic syndromes, because AMPK has been demonstrated to mediate, at least in part, the effects of a number of physiological and pharmacological factors that exert beneficial effects on these disorders. Thus, the identification of a compound that activates the AMPK pathway would contribute significantly to the treatment and management of such syndromes. In service of this goal, we have screened a variety of naturally occurring compounds and have identified one compound, cryptotanshinone, as a novel AMPK pathway activator. Cryptotanshinone was originally isolated from the dried roots of Salvia militorrhiza, an herb that is used extensively in Asian medicine and that is known to exert beneficial effects on the circulatory system. For the first time, in the present study, we have described the potent antidiabetic and antiobesity effects of cryptotanshinone, both in vitro and in vivo. Our findings suggest that the activation of the AMPK pathway might contribute to the development of novel therapeutic approaches for the treatment of metabolic disorders such as type 2 diabetes and obesity.


Received January 23, 2007; accepted April 11, 2007

Address correspondence to: Dr. Joohun Ha, Department of Biochemistry and Molecular Biology, Kyung Hee University School of Medicine, Tongdaemun-gu, Hoegi-dong 1, Seoul 130-701, Korea. E-mail: hajh{at}khu.ac.kr




This article has been cited by other articles:


Home page
Mol. Endocrinol.Home page
E. M. Horvath, L. Tackett, A. M. McCarthy, P. Raman, J. T. Brozinick, and J. S. Elmendorf
Antidiabetogenic Effects of Chromium Mitigate Hyperinsulinemia-Induced Cellular Insulin Resistance via Correction of Plasma Membrane Cholesterol Imbalance
Mol. Endocrinol., April 1, 2008; 22(4): 937 - 950.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics